SK Life Science’s sodium channel antagonist cenobamate was approved based on data from pivotal trials in nearly 2000 patients in which it reduced the median number of seizures per 28 days.
from Front page feed https://ift.tt/35BxLy2
from Front page feed https://ift.tt/35BxLy2
Comments
Post a Comment